Aurobindo Pharma reported INR82.35B in Cash and Equivalent for its fiscal quarter ending in March of 2025.


Cash And Equivalent Change Date
Cipla INR 8B 1.22B Mar/2025
Divis Laboratories Ltd 4.15B 31.87B Mar/2025
Dr.Reddys Laboratories INR 9B 5.65B Jun/2025
Hindustan Unilever INR 60.71B 25.72B Mar/2025
Sun Pharmaceuticals INR 113.32B 33.19B Mar/2025
UPL INR 95.37B 56.27B Mar/2025